Evoke Pharma, Inc. (EVOK)

Evoke Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	5.18	2.51	1.62	0.02	0
Revenue Growth (YoY)	106.51%	55.04%	6929.00%	-	-
Cost of Revenue	0.2	0.37	0.33	0.09	0
Gross Profit	4.98	2.14	1.29	-0.06	0
Selling, General & Admin	12.23	9.62	8.85	6.43	3.74
Research & Development	0.18	0.3	0.59	6.55	3.42
Operating Expenses	12.41	9.92	9.44	12.98	7.15
Operating Income	-7.43	-7.79	-8.15	-13.05	-7.15
Interest Expense / Income	0.5	0.5	0.5	0.11	0
Other Expense / Income	-0.14	-0.06	-0.11	-0.01	-0.03
Pretax Income	-7.79	-8.22	-8.54	-13.15	-7.13
Net Income	-7.79	-8.22	-8.54	-13.15	-7.13
Shares Outstanding (Basic)	3	3	3	2	2
Shares Outstanding (Diluted)	3	3	3	2	2
Shares Change	6.34%	17.21%	26.26%	14.33%	34.29%
EPS (Basic)	-2.33	-2.62	-3.18	-6.24	-3.84
EPS (Diluted)	-2.33	-2.62	-3.18	-6.24	-3.84
Free Cash Flow	-4.98	-6.6	-12.35	-6.63	-5.76
Free Cash Flow Per Share	-1.49	-2.10	-4.61	-3.12	-3.10
Gross Margin	96.10%	85.24%	79.72%	-276.68%	-
Operating Margin	-143.44%	-310.37%	-503.79%	-56678.32%	-
Profit Margin	-150.41%	-327.83%	-527.66%	-57144.53%	-
Free Cash Flow Margin	-96.22%	-262.93%	-763.43%	-28801.07%	-
EBITDA	-7.16	-7.69	-8.04	-13.04	-7.13
EBITDA Margin	-138.27%	-306.42%	-496.76%	-56653.68%	-
Depreciation & Amortization	0.13	0.04	0	0	0
EBIT	-7.29	-7.72	-8.04	-13.04	-7.13
EBIT Margin	-140.76%	-307.90%	-496.76%	-56653.68%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).